Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Molecular correlates of metastasis by systematic pan-cancer analysis across The Cancer Genome Atlas.

Chen F, Zhang Y, Varambally S, Creighton CJ.

Mol Cancer Res. 2018 Nov 6. pii: molcanres.0601.2018. doi: 10.1158/1541-7786.MCR-18-0601. [Epub ahead of print]

PMID:
30401717
2.

Mammary precancerous stem and non-stem cells evolve into cancers of distinct subtypes.

Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li Y.

Cancer Res. 2018 Nov 6. pii: canres.1087.2018. doi: 10.1158/0008-5472.CAN-18-1087. [Epub ahead of print]

PMID:
30401712
3.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

4.

MicroRNAs as prognostic markers in prostate cancer.

Suer I, Guzel E, Karatas OF, Creighton CJ, Ittmann M, Ozen M.

Prostate. 2018 Oct 21. doi: 10.1002/pros.23731. [Epub ahead of print]

PMID:
30345533
5.

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

Classe M, Yao H, Mouawad R, Creighton CJ, Burgess A, Allanic F, Wassef M, Leroy X, Verillaud B, Mortuaire G, Bielle F, Le Tourneau C, Kurtz JE, Khayat D, Su X, Malouf GG.

Cell Rep. 2018 Oct 16;25(3):811-821.e5. doi: 10.1016/j.celrep.2018.09.047.

6.

miR-205 Regulates Basal Cell Identity and Stem Cell Regenerative Potential During Mammary Reconstitution.

Lu Y, Cao J, Napoli M, Xia Z, Zhao N, Creighton CJ, Li W, Chen X, Flores ER, McManus MT, Rosen JM.

Stem Cells. 2018 Sep 29. doi: 10.1002/stem.2914. [Epub ahead of print]

PMID:
30267595
7.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Jul 2;128(7):3198. doi: 10.1172/JCI122740. Epub 2018 Jul 2. No abstract available.

8.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

9.

The clinical applications of The Cancer Genome Atlas project for bladder cancer.

Creighton CJ.

Expert Rev Anticancer Ther. 2018 Oct;18(10):973-980. doi: 10.1080/14737140.2018.1508999. Epub 2018 Aug 13.

PMID:
30081681
10.

TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.

Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL.

Nat Commun. 2018 Jul 16;9(1):2731. doi: 10.1038/s41467-018-05013-x.

11.

In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.

Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, Chen K, Creighton CJ, Fu H, Mills GB, Gibbons DL, Scott KL.

Nat Commun. 2018 Jul 16;9(1):2732. doi: 10.1038/s41467-018-04572-3.

12.

A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases.

Zhang Y, Yang L, Kucherlapati M, Chen F, Hadjipanayis A, Pantazi A, Bristow CA, Lee EA, Mahadeshwar HS, Tang J, Zhang J, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Li W, Park PJ, Kucherlapati R, Creighton CJ.

Cell Rep. 2018 Jul 10;24(2):515-527. doi: 10.1016/j.celrep.2018.06.025.

13.

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.

PMID:
29858753
14.

IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

You R, DeMayo FJ, Liu J, Cho SN, Burt BM, Creighton CJ, Casal RF, Lazarus DR, Lu W, Tung HY, Yuan X, Hill-McAlester A, Kim M, Perusich S, Cornwell L, Rosen D, Song LZ, Paust S, Diehl G, Corry D, Kheradmand F.

Cancer Immunol Res. 2018 Jun;6(6):645-657. doi: 10.1158/2326-6066.CIR-17-0554. Epub 2018 Apr 13.

PMID:
29653981
15.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C.

Cell Rep. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063.

16.

Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.

Palaniappan M, Edwards D, Creighton CJ, Medina D, Conneely OM.

PLoS One. 2018 Mar 28;13(3):e0194913. doi: 10.1371/journal.pone.0194913. eCollection 2018.

17.

Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN.

Shao L, Wang J, Karatas OF, Feng S, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2018 Feb 12;9(18):14456-14471. doi: 10.18632/oncotarget.24470. eCollection 2018 Mar 6.

18.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

PMID:
29578538
19.

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.

Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV.

Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.

PMID:
29574636
20.

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.

Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT.

Nat Commun. 2018 Mar 13;9(1):1057. doi: 10.1038/s41467-018-03476-6.

21.

Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH.

Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7.

PMID:
29514796
22.

Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases.

Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ.

Clin Cancer Res. 2018 May 1;24(9):2182-2193. doi: 10.1158/1078-0432.CCR-17-3378. Epub 2018 Feb 9.

PMID:
29440175
23.

A Landscape of Metabolic Variation across Tumor Types.

Reznik E, Luna A, Aksoy BA, Liu EM, La K, Ostrovnaya I, Creighton CJ, Hakimi AA, Sander C.

Cell Syst. 2018 Mar 28;6(3):301-313.e3. doi: 10.1016/j.cels.2017.12.014. Epub 2018 Jan 27.

PMID:
29396322
24.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

25.

Making Use of Cancer Genomic Databases.

Creighton CJ.

Curr Protoc Mol Biol. 2018 Jan 16;121:19.14.1-19.14.13. doi: 10.1002/cpmb.49.

PMID:
29337373
26.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Apr 2;128(4):1267-1282. doi: 10.1172/JCI97225. Epub 2018 Feb 26.

27.

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.

Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ.

J Pathol. 2018 Apr;244(5):525-537. doi: 10.1002/path.5022. Epub 2018 Feb 14. Review.

PMID:
29266437
28.

Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.

El-Shennawy L, Dubrovskyi O, Kastrati I, Danes JM, Zhang Y, Whiteley HE, Creighton CJ, Frasor J.

Cancer Res. 2018 Feb 15;78(4):974-984. doi: 10.1158/0008-5472.CAN-17-1686. Epub 2017 Dec 11.

PMID:
29229606
29.

Influence of the neural microenvironment on prostate cancer.

Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, Ragheb A, Frolov A, Michailidis G, Lee M, Kadmon D, Miles B, Smith C, Ittmann M, Rowley D, Sreekumar A, Creighton CJ, Ayala G.

Prostate. 2018 Feb;78(2):128-139. doi: 10.1002/pros.23454. Epub 2017 Nov 13.

30.

WNT-Mediated Regulation of FOXO1 Constitutes a Critical Axis Maintaining Pubertal Mammary Stem Cell Homeostasis.

Sreekumar A, Toneff MJ, Toh E, Roarty K, Creighton CJ, Belka GK, Lee DK, Xu J, Chodosh LA, Richards JS, Rosen JM.

Dev Cell. 2017 Nov 20;43(4):436-448.e6. doi: 10.1016/j.devcel.2017.10.007. Epub 2017 Nov 2.

PMID:
29103953
31.

Daam2 driven degradation of VHL promotes gliomagenesis.

Zhu W, Krishna S, Garcia C, Lin CJ, Mitchell BD, Scott KL, Mohila CA, Creighton CJ, Yoo SH, Lee HK, Deneen B.

Elife. 2017 Oct 20;6. pii: e31926. doi: 10.7554/eLife.31926.

32.

miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Karatas OF, Wang J, Shao L, Ozen M, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2017 Jul 24;8(36):60243-60256. doi: 10.18632/oncotarget.19521. eCollection 2017 Sep 1.

33.

Glia-specific enhancers and chromatin structure regulate NFIA expression and glioma tumorigenesis.

Glasgow SM, Carlson JC, Zhu W, Chaboub LS, Kang P, Lee HK, Clovis YM, Lozzi BE, McEvilly RJ, Rosenfeld MG, Creighton CJ, Lee SK, Mohila CA, Deneen B.

Nat Neurosci. 2017 Nov;20(11):1520-1528. doi: 10.1038/nn.4638. Epub 2017 Sep 11.

34.

Macrophages promote the progression of premalignant mammary lesions to invasive cancer.

Carron EC, Homra S, Rosenberg J, Coffelt SB, Kittrell F, Zhang Y, Creighton CJ, Fuqua SA, Medina D, Machado HL.

Oncotarget. 2017 Jan 31;8(31):50731-50746. doi: 10.18632/oncotarget.14913. eCollection 2017 Aug 1.

35.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

36.

Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.

Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM.

Sci Rep. 2017 Jul 25;7(1):6478. doi: 10.1038/s41598-017-06922-5.

37.

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S.

Neoplasia. 2017 Aug;19(8):649-658. doi: 10.1016/j.neo.2017.05.002. Epub 2017 Jul 18.

38.

Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression.

Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM.

Oncogene. 2017 Oct 26;36(43):5958-5968. doi: 10.1038/onc.2017.206. Epub 2017 Jun 26.

39.

A Role for Progesterone-Regulated sFRP4 Expression in Uterine Leiomyomas.

Delaney MA, Wan YW, Kim GE, Creighton CJ, Taylor MG, Masand R, Park A, Valdes C, Gibbons W, Liu Z, Anderson ML.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3316-3326. doi: 10.1210/jc.2016-4014.

40.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ.

JCI Insight. 2017 Jun 15;2(12). pii: 92688. doi: 10.1172/jci.insight.92688. [Epub ahead of print]

41.

RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Wang Y, Wang J, Zhang L, Karatas OF, Shao L, Zhang Y, Castro P, Creighton CJ, Ittmann M.

Cancer Res. 2017 Aug 15;77(16):4247-4257. doi: 10.1158/0008-5472.CAN-17-0669. Epub 2017 Jun 13.

42.

Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.

Casadei L, Calore F, Creighton CJ, Guescini M, Batte K, Iwenofu OH, Zewdu A, Braggio DA, Bill KL, Fadda P, Lovat F, Lopez G, Gasparini P, Chen JL, Kladney RD, Leone G, Lev D, Croce CM, Pollock RE.

Cancer Res. 2017 Jul 15;77(14):3846-3856. doi: 10.1158/0008-5472.CAN-16-2984. Epub 2017 Jun 6.

43.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

44.

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.

Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, Kim YW, Creighton CJ, Verhaak RG, Mills GB, Park PJ, Kucherlapati R, Scott KL.

Cancer Res. 2017 Jul 1;77(13):3502-3512. doi: 10.1158/0008-5472.CAN-16-2745. Epub 2017 May 16.

45.

A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis.

Wang W, Meng Y, Dong B, Dong J, Ittmann MM, Creighton CJ, Lu Y, Zhang H, Shen T, Wang J, Rowley DR, Li Y, Chen F, Moore DD, Yang F.

Neoplasia. 2017 May;19(5):421-428. doi: 10.1016/j.neo.2017.03.003. Epub 2017 Apr 20.

46.

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, Lekaye CL, Koutcher JA, Leslie CS, Creighton CJ, Weinhold N, Lee W, Tickoo SK, Wang Z, Cheng EH, Hsieh JJ.

Cell Rep. 2017 Mar 21;18(12):2893-2906. doi: 10.1016/j.celrep.2017.02.074.

47.

Decreased epithelial progesterone receptor A at the window of receptivity is required for preparation of the endometrium for embryo attachment.

Wetendorf M, Wu SP, Wang X, Creighton CJ, Wang T, Lanz RB, Blok L, Tsai SY, Tsai MJ, Lydon JP, DeMayo FJ.

Biol Reprod. 2017 Feb 1;96(2):313-326. doi: 10.1095/biolreprod.116.144410.

48.

Identification of diverse astrocyte populations and their malignant analogs.

John Lin CC, Yu K, Hatcher A, Huang TW, Lee HK, Carlson J, Weston MC, Chen F, Zhang Y, Zhu W, Mohila CA, Ahmed N, Patel AJ, Arenkiel BR, Noebels JL, Creighton CJ, Deneen B.

Nat Neurosci. 2017 Mar;20(3):396-405. doi: 10.1038/nn.4493. Epub 2017 Feb 6.

49.

Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas.

Gibbons DL, Creighton CJ.

Dev Dyn. 2018 Mar;247(3):555-564. doi: 10.1002/dvdy.24485. Epub 2017 May 4.

PMID:
28073171
50.

Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.

Zeng H, Ortiz A, Shen PF, Cheng CJ, Lee YC, Yu G, Lin SC, Creighton CJ, Yu-Lee LY, Lin SH.

Oncotarget. 2017 Feb 7;8(6):10145-10160. doi: 10.18632/oncotarget.14358.

Supplemental Content

Loading ...
Support Center